Artificial Mini Dendritic Cells Boost T Cell-Based Immunotherapy for Ovarian Cancer.

ABSTRACT: Ovarian cancer is the most lethal gynecological malignancy with high recurrence rates and low survival rates, remaining a disease of high unmet need. Cancer immunotherapy, which harnesses the potential of the immune system to attack tumors, has emerged as one of the most promising treatment options in recent years. As an important form of immunotherapy, dendritic cell (DC)-based vaccines have demonstrated the ability to induce an immune response, while clinical efficacy of DC vaccines remains unsubstantiated as long-term benefit is only reported in a restricted proportion of patients. Here, a biomimetic nanovaccine derived from DCs is developed through cell membrane coating nanotechnology. This nanovaccine, denoted "mini DC," inherits the ability of antigen presentation and T cells' stimul

SUBMITTER: Cheng S 

PROVIDER: S-EPMC7141030 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature